No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.
作者信息
Molina J M, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N
机构信息
Infectious Diseases Department, AP-HP-Saint-Louis Hospital, 1, avenue Claude-Vellefaux 75010 Paris, France; U944 INSERM, université de Paris, 75000 Paris, France.
Université de Paris, 75000 Paris, France; Virology Department, AP-HP-Saint-Louis Hospital, 75010 Paris, France.
出版信息
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
Abstract
摘要
相似文献
1
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
2
Audio Interview: Studying Potential Covid-19 Therapies.音频访谈：研究潜在的新冠病毒治疗方法。
N Engl J Med. 2020 May 7;382(19):e72. doi: 10.1056/NEJMe2015955.
3
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.羟氯喹和阿奇霉素联合治疗 COVID-19 患者：法国马赛 1061 例回顾性分析。
Travel Med Infect Dis. 2020 May-Jun;35:101738. doi: 10.1016/j.tmaid.2020.101738. Epub 2020 May 5.
4
Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?羟氯喹联合阿奇霉素是否仍将成为 COVID-19 的游戏规则改变者？
Front Immunol. 2020 Aug 7;11:1969. doi: 10.3389/fimmu.2020.01969. eCollection 2020.
5
Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?羟氯喹和阿奇霉素用于治疗新冠肺炎患者：是益友还是劲敌？
J Clin Pharmacol. 2020 Jul;60(7):808-814. doi: 10.1002/jcph.1646. Epub 2020 May 20.
6
Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.大环内酯类药物与病毒感染：聚焦 COVID-19 病理学中的阿奇霉素。
Int J Antimicrob Agents. 2020 Aug;56(2):106053. doi: 10.1016/j.ijantimicag.2020.106053. Epub 2020 Jun 10.
7
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?羟氯喹作为 COVID-19 的预防或治疗药物：证据说了什么？
Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20.
8
Acute meningoencephalitis in a patient with COVID-19.一名新冠肺炎患者出现急性脑膜脑炎。
Rev Neurol (Paris). 2020 Jun;176(6):519-521. doi: 10.1016/j.neurol.2020.04.014. Epub 2020 May 11.
9
Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.COVID-19 住院患者中阿奇霉素和羟氯喹的主动预防（ProPAC-COVID）：统计分析计划。
Trials. 2020 Oct 20;21(1):867. doi: 10.1186/s13063-020-04795-0.
10
Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome.羟氯喹啉和阿奇霉素作为新型冠状病毒肺炎的潜在治疗药物；临床状况影响治疗结果。
J Pharmacokinet Pharmacodyn. 2020 Jun;47(3):187-188. doi: 10.1007/s10928-020-09689-x. Epub 2020 May 13.
引用本文的文献
1
Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update.对抗新型冠状病毒肺炎的新兴治疗与预防策略：简要更新
J Dig Endosc. 2020 Mar;11(1):69-72. doi: 10.1055/s-0040-1712547. Epub 2020 May 16.
2
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效：III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
3
The II Brazilian Guidelines for the pharmacological treatment of patients hospitalized with COVID-19 Joint Guidelines of the Associação Brasileira de Medicina de Emergência, Associação de Medicina Intensiva Brasileira, Associação Médica Brasileira, Sociedade Brasileira de Angiologia e Cirurgia Vascular, Sociedade Brasileira de Infectologia, Sociedade Brasileira de Pneumologia e Tisiologia and Sociedade Brasileira de Reumatologia.《巴西第二版 COVID-19 住院患者药物治疗指南》联合指南：巴西急诊医学协会、巴西重症监护医学协会、巴西医师协会、巴西血管和血管外科学会、巴西传染病学会、巴西肺病学会和结核病学会以及巴西风湿病学会。
Crit Care Sci. 2023 Dec 22;35(3):243-255. doi: 10.5935/2965-2774.20230136-en. eCollection 2023.
4
Doxycycline vs Hydroxychloroquine + Azithromycin in the Management of COVID-19 Patients: An Open-Label Randomized Clinical Trial in Sub-Saharan Africa (DOXYCOV).多西环素与羟氯喹啉联合阿奇霉素治疗新冠肺炎患者的疗效对比：撒哈拉以南非洲地区的一项开放标签随机临床试验（DOXYCOV）
Cureus. 2023 Sep 20;15(9):e45619. doi: 10.7759/cureus.45619. eCollection 2023 Sep.
5
Impact of prophylactic hydroxychloroquine on ultrastructural impairment and cellular SARS-CoV-2 infection in different cells of bronchoalveolar lavage fluids of COVID-19 patients.羟氯喹预防对 COVID-19 患者支气管肺泡灌洗液不同细胞中超微结构损伤和细胞内 SARS-CoV-2 感染的影响。
Sci Rep. 2023 Aug 5;13(1):12733. doi: 10.1038/s41598-023-39941-6.
6
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.新型冠状病毒肺炎（COVID-19）治疗方法：旧药新用的临床应用及基于靶点的药物发现的未来策略
Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7.
7
Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection.血浆置换对因严重COVID-19感染而发生细胞因子风暴的中性粒细胞减少患者的疗效。
Blood Res. 2023 Jun 30;58(2):91-98. doi: 10.5045/br.2023.2022201. Epub 2023 May 10.
8
Discovery of Potential Inhibitors of SARS-CoV-2 Main Protease by a Transfer Learning Method.基于迁移学习方法发现 SARS-CoV-2 主要蛋白酶的潜在抑制剂。
Viruses. 2023 Mar 30;15(4):891. doi: 10.3390/v15040891.
9
Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study.免疫增强、抗氧化和抗炎食品补充剂对住院 COVID-19 患者的影响：一项前瞻性随机试点研究。
Nutrients. 2023 Apr 1;15(7):1736. doi: 10.3390/nu15071736.
10
Advances in natural product anti-coronavirus research (2002-2022).天然产物抗冠状病毒研究进展（2002 - 2022年）
Chin Med. 2023 Feb 13;18(1):13. doi: 10.1186/s13020-023-00715-x.
本文引用的文献
1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
2
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
3
Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection.氯喹治疗增强基孔肯雅热病毒感染的矛盾效应。
Viruses. 2018 May 17;10(5):268. doi: 10.3390/v10050268.
4
Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases.通过氯喹类似物靶向内体酸化作为治疗新出现病毒性疾病的一种有前景的策略。
Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293. doi: 10.1002/prp2.293. eCollection 2017 Feb.
5
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.羟氯喹对未接受抗逆转录病毒治疗的 HIV 感染患者免疫激活和疾病进展的影响：一项随机对照试验。
JAMA. 2012 Jul 25;308(4):353-61. doi: 10.1001/jama.2012.6936.
6
Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial.氯喹预防流感：一项随机、双盲、安慰剂对照试验。
Lancet Infect Dis. 2011 Sep;11(9):677-83. doi: 10.1016/S1473-3099(11)70065-2. Epub 2011 May 5.
7
A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults.一项在越南成年人中氯喹治疗登革热的随机对照试验。
PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785. doi: 10.1371/journal.pntd.0000785.
Zotero 插件